[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"organoids\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:organoids":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,72,100,127,148,177,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100587550","organoid-models-of-hepatocellular-carcinoma-100587550",false,"NCT06929845","Organoid Models of Hepatocellular Carcinoma","Organoid Models of Hepatocellular Carcinoma to Test Treatment Efficacy, Exploring Correlations With Tumor Microenvironment and Gut-liver-tumor Axis.","Inclusion Criteria:\n\n* Capacity to express informed consent;\n* Age ≥18 years;\n* Suspected radiological diagnosis of HCC or diagnosis of HCC with indications for surgical resection.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Contraindications to liver biopsy (ascites, platelets\\\u003C50,000, INR\\>1.7);\n* Contraindications to HCC resection surgery;\n* Active viral infection;\n* Refusal to sign informed consent to participate in the study.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","A promising tool to elucidate the molecular characteristics of HCC are patient-derived organoids (PDOs), three-dimensional cultures of cells that self-organise according to tissue-specific patterns and can be used to test the susceptibility of a specific tumour to anticancer agents. In this study, PDOs for HCC will be developed that closely resemble the tumour microenvironment in vivo and mimic the crosstalk of the gut-liver axis to establish a correlation with patient prognosis and test the efficacy of available systemic therapies.",[26,27,28,29,30,31],"Hepatocellular Carcinoma","Organoids","Gut Microbiota","Tumor Microenvironment","System Disorders, Digestive","Surgery","RECRUITING","2026-05-18",{"date":35,"type":36},"2026-05-19","ACTUAL",{"date":38,"type":36},"2024-10-01",{"date":40,"type":20},"2026-12-31",{"name":42,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100585820","phase-2-testing-a-functional-precision-medicine-approach-to-select-chemotherapy-for-metastatic-colorectal-cancer-cosense-1-100585820","NCT06907342","Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)","COSENSE-1: A Feasibility Study for Using a Functional Precision Medicine Platform to Select Oxaliplatin-based Versus Irinotecan-based Chemotherapy Regimens for Patients With Metastatic Colorectal Cancer","COSENSE-1","Inclusion Criteria:\n\nGeneral conditions:\n\n1. Age 18 or older\n2. ECOG performance status 0 or 1\n3. Obtained informed consent\n4. Acceptable organ function (defined in publicly available protocol)\n5. Women of child-bearing potential and men must agree to use highly effective contraception (defined in publicly available protocol)\n\n   Disease and treatment specific conditions:\n6. Histologically confirmed pMMR\u002FMSS adenocarcinoma originating from the colon or rectum\n7. Unresectable metastatic disease (not amenable to radical surgery of the cancer disease at the time of study inclusion)\n8. Patient has metastatic or primary lesion available for biopsy\n9. Patient has measurable or evaluable disease per RECIST (version 1.1)\n10. The oxaliplatin-based regimen FOLFOX (+\u002F- antibody) versus the irinotecan-based regimen FOLFIRI (+\u002F- antibody), are evaluated by an experienced physician, independent of inclusion in the trial, to be equally recommended for the participant as standard of care first-line therapy in the treatment of mCRC, following the Norwegian national guideline on the treatment of colorectal cancer (https:\u002F\u002Fwww.helsedirektoratet.no\u002Fretningslinjer\u002Fkreft-i-tykktarm-og-endetarm-handlingsprogram)\n11. Patient is eligible for full (100%) chemotherapy doses at first treatment cycle\n12. Treatment with chemotherapy can be scheduled within 28 days from referral\n\nExclusion Criteria:\n\n1. Patient has metastatic MMR deficient\u002FMSI adenocarcinoma\n2. Patient is ineligible for full (100%) chemotherapy doses at first treatment cycle\n3. Patient is not equally eligible for FOLFOX (+\u002F- antibody) and FOLFIRI (+\u002F- antibody) chemotherapy regimens, according to the Norwegian national guideline on the treatment of colorectal cancer\n4. ECOG performance status 2 or worse\n5. Pregnancy or planned pregnancy during the study period, due to the risks of drug treatment to a developing foetus\n6. Breastfeeding\n7. Patients with psychological, geographical, familial or sociological conditions that can prevent compliance with the study protocol\n8. Inability to understand study procedures and comply with them, or disorder that compromises the patient's ability to provide informed consent and\u002For comply with study procedures\n9. Patient fulfils any of the contraindications listed in the SmPC of the relevant IMP\n10. Treatment cannot be scheduled within 28 days from referral\n\n    Medical history:\n11. Partial or complete dihydropyrimidine dehydrogenase (DPD) deficiency\n12. Evidence of CNS metastasis\n13. Unresolved toxicities of a previous systemic treatment that, in the opinion of the physician, make the patient unfit for inclusion\n14. Antitumoural treatment ≤ 30 days before inclusion. Hormonal substitutive treatment is allowed\n15. Preexisting significant cardiovascular disease including uncontrolled\u002Funstable or symptomatic angina, uncontrolled atrial or ventricular arrythmias, LVEF known to be \\\u003C 40% or symptomatic congestive heart failure\n16. Stroke (including TIA) or acute myocardial infarction within 6 months before the first dose of study treatment\n17. Clinically significant peripheral sensory neuropathy\n18. Recent (\\\u003C6 months before the start of study treatment) pulmonary embolism, deep vein thrombosis, or another significant thromboembolic event\n19. History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on chest computed tomography (CT)\n20. Evidence of previous acute hypersensitivity reaction to any component of the treatment\n21. History of any disease that may increase the risks associated with study participation",{"count":54,"type":20},148,[56],"PHASE2","COSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)\u002Fproficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), that is incurable or not resectable with curative intent.",[59,27,60,61,62,63],"Tumor, Colorectal","Tumoroid","Metastatic Colorectal Cancer","Core Needle Biopsy","First-line Treatment","2025-05-23",{"date":66,"type":36},"2025-05-25",{"date":64,"type":36},{"date":69,"type":20},"2040-09",{"name":71,"class":43},"St. Olavs Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100590529","analysis-of-early-neurodevelopmental-alterations-in-bipolar-disorder-based-on-cortical-organoid-models-100590529","NCT06968598","Analysis of Early Neurodevelopmental Alterations in Bipolar Disorder Based on Cortical Organoid Models","BIPODEV","Inclusion Criteria:\n\n* Presence of bipolar disorder according to DSM-5 criteria\n* Able to freely give and sign consent\n* Affiliated or beneficiary of a health insurance plan\n* Previous participants in the NEMO study (2022-A00353-40)\n\nFor the \"neurodevelopmental bipolar\" (ND-BP) group: presence of a neurodevelopmental burden score in the top 5, as assessed in the NEMO project (NCT05674019).\n\nFor the \"non-neurodevelopmental bipolar\" group (TB): presence of a neurodevelopmental load score of 0, or in the lowest 5, as assessed in the NEMO project.\n\nExclusion Criteria:\n\n* \\- Presence of a severe symptomatic or unstable physiological or medical condition (including pregnancy)\n* History of psychiatric illness (stable or not), schizophrenia or any other pathology likely to interfere with bipolar disorder\n* History of severe head trauma (GCS\\\u003C8 at time of trauma)\n* Presence of a neurological disorder affecting central nervous system function\n* Presence of moderate to severe substance use disorders (\\>=4\u002F11 as defined in DSM-5), with the exception of tobacco use disorders.\n* The volunteer is under court protection or guardianship\n* It proves impossible to give the volunteer informed information, or the volunteer refuses to sign the consent form.\n* Insufficient command of the French language to complete evaluations","60 Years",{"count":81,"type":20},10,[23],"Demonstrate the existence of neurodevelopmental alterations in organoids derived from samples of patients with bipolar disorder (BD) with a neurodevelopmental (ND) component, compared with patients with bipolar disorder (BD) without an ND component.",[85,27,86],"Bipolar Disorder (BD)","Neurodevelopmental Conditions",[88,89],"organoid","neurodevelopmental alterations","NOT_YET_RECRUITING","2025-05-05",{"date":93,"type":36},"2025-05-13",{"date":95,"type":20},"2025-06-01",{"date":97,"type":20},"2030-02-01",{"name":99,"class":43},"Assistance Publique Hopitaux De Marseille",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100566661","drug-sensitivity-of-hydrothorax-and-ascite-organoids-from-breast-cancer-100566661","NCT06658080","Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer","Drug Sensitivity Based on Hydrothorax and Ascite Organoids Derived from Metastasic Breast Cancer","Inclusion Criteria:\n\n1. Signed informed consent form and willingness to participate in the clinical study.\n2. patients aged between 18 and 70 years old.\n3. Confirmed metastatic breast cancer patients with hydrothorax and ascite fluid, which was verified to contain tumor cells by lab.\n4. ECOG performance status score of 0-1.\n5. No significant abnormalities in liver and kidney function (BIL \\\u003C1.5-fold upper limit of normal (ULN)；ALT\\\u003C2.5×ULN; AST\\\u003C2.5×ULN；Crea≤1×ULN).\n\nExclusion Criteria:\n\n1.Patients not suitable for chemotherapy and target therapy","70 Years",{"count":109,"type":20},90,"OBSERVATIONAL","Malignant hydrothorax and ascitic fluid in advanced breast cancer often arise from metastasis to the lungs, pleura, or liver. Patients with this condition experience rapid disease progression and multidrug resistance, facing limited treatment options. Clinical guidelines offer various therapies based on molecular subtypes; however, their effectiveness can be hindered by prior treatments, patient health, and tumor evolution. Current evaluations of treatment efficacy typically take two cycles, delaying the recognition of ineffective therapies and resulting in unnecessary side effects and costs. Organoid models present a promising solution, accurately replicating tumor structure and cellular diversity compared to traditional methods. These patient-derived models facilitate improved drug sensitivity testing, leading to more personalized treatment plans. In this study, 90 patients diagnosed with metastatic breast cancer accompanied by hydrothorax and ascitic fluid will be recruited. Patient-derived organoids will be used to assess the sensitivity of chemotherapy regimens, including Doxorubicin, Carboplatin, Cyclophosphamide, and Paclitaxel, along with targeted therapies such as Herceptin and Pertuzumab.",[113,114,115,27,116],"Breast Cancer Metastatic","Hydrothorax","Ascites","Drug Evaluation","2025-01-05",{"date":119,"type":36},"2025-01-07",{"date":121,"type":36},"2024-11-09",{"date":123,"type":20},"2027-10-25",{"name":125,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University",3,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":135,"minAge":17,"maxAge":107,"enrollmentInfo":136,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":44},"100528018","organoids-based-drug-sensitivity-in-neoadjuvant-chemotherapy-of-breast-cancer-100528018","NCT06155305","Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer","Consistency of Organoids Based Drug Sensitivity and Efficacy of Neoadjuvant Chemotherapy in Breast Cancer","ONAC","Inclusion Criteria:\n\n1. Signed informed consent form and willingness to participate in the clinical study.\n2. Female patients aged between 18 and 70 years old.\n3. Confirmed early-stage breast cancer eligible for surgery (AJCC stages I to IIIA), with a tumor diameter of ≥ 2cm detected by MRI and without distant metastasis (M0).\n\n   The largest lesion among multiple lesions has a diameter of ≥ 2cm.\n4. ECOG performance status score of 0-1.\n5. No significant abnormalities in liver and kidney function (BIL \\\u003C1.5-fold upper limit of normal (ULN)；ALT\\\u003C2.5×ULN; AST\\\u003C2.5×ULN；Crea≤1×ULN).\n\nExclusion Criteria:\n\n1. Received prior treatments.\n2. Locally advanced breast cancer not amenable to surgery or inflammatory breast cancer (AJCC stage unresectable III).\n3. Bilateral breast cancer.\n4. Multiple breast cancers distributed in different quadrants.\n5. Patients not suitable for neoadjuvant chemotherapy.","FEMALE",{"count":137,"type":20},58,"Breast cancer is the most common malignancy in women worldwide. Patients with breast cancer are often diagnosed at later stages and have a strong desire for breast conservation, necessitating neoadjuvant chemotherapy. Tumors of different molecular subtypes and individual variations among patients lead to significant differences in treatment efficacy. Precise assessment of patients' responses to treatment regimens is imperative in advancing prognosis of breast cancer. In this study, 58 patients diagnosed with breast cancer and scheduled for neoadjuvant therapy will be recruited. Patient-derived organoids from their tumor biopsies will be utilized to evaluate the sensitivity of chemotherapy regimen. These drugs primarily include Doxorubicin, Carboplatin, Cyclophosphamide, Paclitaxel, as well as targeted therapies such as Herceptin and Pertuzumab.",[27,140,141],"Breast Cancer","Neoadjuvant Chemotherapy",{"date":119,"type":36},{"date":144,"type":36},"2023-12-06",{"date":146,"type":20},"2025-12-01",{"name":125,"class":43},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":157,"targetDuration":159,"studyType":110,"phases":4,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":44},"100464104","bern-human-organoid-study-to-study-host-microbe-interaction-100464104","NCT05323357","Bern Human Organoid-Study to Study Host-microbe Interaction","Establishment of Human Organoid Lines as a Tool to Dissect Molecular Pathways of Host-microbiota Interactions","humorg","Inclusion Criteria:\n\n* Signed informed consent\n* Indication for upper or lower endoscopic procedure\n* Ability to understand and follow study procedures and understand informed consent\n* Age 18-80 years\n* Negative pregnancy test result prior to study enrollment of female study participants (test will be performed prior to enrollment)\n* BMI between 18.5 and 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Disease known to chronically affect gut microbiota, gut epithelium or gut-associated immune system, namely inflammatory bowel disease, diverticulitis, microscopic colitis, liver cirrhosis, malignancy within the digestive tract, systemic sclerosis, coeliac disease, common-variable immunodeficiency, diabetes mellitus\n* Medication with immunosuppressants (e.g. corticoids, biological therapy)\n* Current diagnosis of a hematological disorder (e.g. anemia with hemoglobin \\\u003C7 g\u002Fdl, leukemia) or any other absolute contraindication for blood draw\n* Women who are pregnant\n* Serious coagulation disorder, relevant thrombocytopenia (\\\u003C50'000\u002Ful), double platelet-inhibition, oral anticoagulation (ASS therapy is possible)\n* Known or suspected non-compliance, drug, or alcohol abuse\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant\n* Previous enrolment into the current study\n* Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons\n* Inability or unwillingness to provide blood samples and tissue samples (biopsies)\n* Participants taking oral anticoagulant or with bleeding disorders who would be at much higher risk of bleeding after biopsy samples or who are contraindicated for an endoscopic examination\n* Patients unable to give informed consent\n* Patients that have been under antibiotic therapy in the last 4 weeks\n* Participation in other clinical study interfering with study procedures\n* Potential study participants that wish not to be informed about random results acquired during the study (e.g., during endoscopy or genetic analysis) relevant for their health and for prevention of diseases","80 Years",{"count":158,"type":20},100,"1 Day","The human body inhabits a complex consortium of different microbes which together form the microbiota. Virtually every surface of the human body is colonized by a distinct microbiota, forming complex communities. An increasing number of research results indicates that changes in the microbiota can have vast effects on the health of its host.\n\nMost studies investigating the microbiota were conducted on animals, as many interventions and investigations cannot be performed on humans due to ethical considerations. This raises the question if findings from experimental studies are translational and can benefit patients. That becomes especially apparent when trying to dissect molecular mechanisms involved in this fine-tuned interplay between nutrients, the microbiota, and its host.\n\nBy establishing human organoid cultures from the large and small intestine that can be exposed to microbes and\u002For microbial products with subsequent transcriptomic, epigenetic and immunological analysis, the investigators aim to generate findings with high translational potential with new insights into the complex interaction of the microbiota, the host and its immune system.",[27,162,163],"Allergy and Immunology","Microbiota",[165,166,167],"Enteroids","Host-Microbiota","Mucosal Immunology","2024-12-05",{"date":170,"type":36},"2024-12-11",{"date":172,"type":36},"2022-03-31",{"date":174,"type":20},"2026-03-30",{"name":176,"class":43},"Insel Gruppe AG, University Hospital Bern",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":185,"targetDuration":187,"studyType":110,"phases":4,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100540363","breast-cancer-subtype-characterization-through-patients-derived-organoids-100540363","NCT06315868","Breast Cancer Subtype Characterization Through Patient's Derived Organoids.","Breast Cancer Subtype Characterization Through Patient's Derived Organoids\". (BCinsightPDO)","BCinsightPDO","Inclusion Criteria:\n\n* women diagnosed with primary BC, eligible for surgical resection of the tumor according to national and international guidelines.\n\nage between 18 and 70 years; newly diagnosed breast neoplasms, tumor size of at least 1.5 cm diameter.\n\nExclusion Criteria:\n\nbreast cancer diagnosed during pregnancy, neoadiuvant chemotherapy",{"count":186,"type":20},306,"5 Years","Development of tools to predict patients chemo-sensitivity and identification of corresponding biomarkers is an urgent challenge for BC patients lacking targeted therapies, such as TNBC, or for patients experiencing relapse after adjuvant chemotherapy or targeted therapies.\n\nThe refinement of 3D-cultivation techniques, experienced in the last decade, has allowed cultivation of patients-derived cancer cells in organotypic structures, named patient-derived organoids (PDO), which preserve histologic, genomic and transcriptomic features of primary tumors. PDO allow propagation, pharmacological treatment and genetic manipulation of patients-derived cancer cells in a close to physiology setting, thus representing a promising tool in the development of personalized therapies",[140,27],[191,192,193],"breast cancer","new drugs","organoids","2024-03-11",{"date":196,"type":36},"2024-03-18",{"date":198,"type":36},"2023-06-15",{"date":200,"type":20},"2027-06-15",{"name":42,"class":43},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":208,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100488794","clinical-transformation-of-organoid-model-to-predict-the-efficacy-of-gc-in-the-treatment-of-intrahepatic-cholangiocarcinoma-100488794","NCT05644743","Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma","Inclusion Criteria:\n\n\\- Histologically confirmed intrahepatic cholangiocarcinoma They are between 18 and 80 years old Written informed and signed consent form Biopsy sample of the intrahepatic bile duct\n\nExclusion Criteria:\n\n\\- Under 18, over 80 Informed consent cannot be given Biopsy samples were not available",{"count":209,"type":20},40,"The clinical incidence of intrahepatic cholangiocarcinoma (ICC) is high and insidious, and the prognosis of advanced patients is poor. The clinical manifestations of traditional chemotherapy GC and emerging targeted therapy are different in most patients, and there is still no effective scheme to evaluate the differences in individual patient reactivity. Patient-derived tumor organoids (PDO) are 3D-cultured tissues based on tumor cell dryness that reproduce a variety of biological characteristics of parental tumors in vitro and have similar drug responsiveness to tumors in vivo. This project plans to use clinical cases and optimized organoid culture system to first construct relevant organoids from unresectable ICC patient puncture samples. Secondly, based on the organoid model of intrahepatic cholangiocarcinoma, the clinical efficacy of GC regimen was predicted, and in vitro and in vivo drug screening was conducted to explore the guidance of patient-derived tumor organoids for clinical treatment. Then, multi-omics data of organoids and in vitro and in vivo drug efficacy evaluation model were used to explore the drug resistance genes of intrahepatic cholangiocarcinoma, providing the basis for personalized drug screening and efficacy evaluation of intrahepatic cholangiocarcinoma.",[27,212],"Intrahepatic Cholangiocarcinoma",[214],"Organoid","2022-11-30",{"date":217,"type":36},"2022-12-09",{"date":219,"type":20},"2023-01",{"date":221,"type":20},"2026-12",{"name":223,"class":43},"Chengjun Sui,MD"]